Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,068,626 papers from all fields of science
Search
Sign In
Create Free Account
monoclonal antibody CNTO 328
Known as:
CNTO-328
, monoclonal antibody CNTO-328
, CNTO 328 monoclonal antibody
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
siltuximab
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
A novel approach for the simultaneous quantification of a therapeutic monoclonal antibody in serum produced from two distinct host cell lines
Brian J. Geist
,
Darryl L Davis
,
+5 authors
H. Davis
mAbs
2013
Corpus ID: 20237365
Therapeutic monoclonal antibodies (mAbs) possess a high degree of heterogeneity associated with the cell expression system…
Expand
Review
2012
Review
2012
Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm
S. Pal
,
Stephen Williams
,
D. Josephson
,
C. Carmichael
,
N. Vogelzang
,
D. Quinn
Molecular Cancer Therapeutics
2012
Corpus ID: 2546650
With six agents approved for metastatic renal cell carcinoma (mRCC) within the past 5 years, there has undoubtedly been progress…
Expand
Highly Cited
2009
Highly Cited
2009
Targeted inhibition of interleukin‐6 with CNTO 328 sensitizes pre‐clinical models of multiple myeloma to dexamethasone‐mediated cell death
P. Voorhees
,
Qing Chen
,
+4 authors
R. Orlowski
British Journal of Haematology
2009
Corpus ID: 30638961
Interleukin (IL)‐6‐mediated signalling attenuates the anti‐myeloma activity of glucocorticoids (GCs). We therefore sought to…
Expand
Review
2009
Review
2009
Targeting IL-6 in the treatment of inflammatory and autoimmune diseases
C. Ding
,
F. Cicuttini
,
Jun Li
,
G. Jones
Expert Opinion on Investigational Drugs
2009
Corpus ID: 40835086
Background: IL-6, a glycoprotein composed of 212 amino acids in human, has a wide range of biological activity, including…
Expand
2008
2008
A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease.
R. Kurzrock
,
L. Fayad
,
+11 authors
F. Rhee
2008
Corpus ID: 78938412
Interleukin (IL)-6 is a multifunctional cytokine that serves as a growth factor for B-cell non-Hodgkin’s lymphoma (NHL), multiple…
Expand
2006
2006
Regulation of growth of prostate cancer cells selected in the presence of interleukin‐6 by the anti‐interleukin‐6 antibody CNTO 328
H. Steiner
,
I. Cavarretta
,
+8 authors
Z. Culig
The Prostate
2006
Corpus ID: 39597331
Interleukin‐6 (IL‐6) is a multifunctional regulator of cellular events in prostate cancer. LNCaP‐IL‐6+ cells selected in the…
Expand
2006
2006
Gateways to clinical trials.
M. Bayes
,
X. Rabasseda
,
J. Prous
Methods and Findings in Experimental and Clinical…
2006
Corpus ID: 41805570
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data the…
Expand
2006
2006
Phase I, multicenter trial of CNTO 328, an anti-interleukin(IL)-6 monoclonal antibody (mAb) in subjects with selected hematologic malignancies.
R. Kurzrock
,
P. Voorhees
,
+7 authors
C. Garay
Journal of Clinical Oncology
2006
Corpus ID: 37889089
2513 Background: IL-6 is implicated in the pathophysiology of several malignant diseases, including multiple myeloma (MM) and…
Expand
Review
2005
Review
2005
CNTO-328 (Centocor).
J. Li
,
X. Hu
,
P. Xing
Current opinion in investigational drugs
2005
Corpus ID: 35960024
Highly Cited
2004
Highly Cited
2004
CNTO 328, a monoclonal antibody to IL‐6, inhibits human tumor‐induced cachexia in nude mice
M. Zaki
,
J. Nemeth
,
M. Trikha
International Journal of Cancer
2004
Corpus ID: 22478793
IL‐6 is a multifunctional cytokine implicated in several cancers. IL‐6 is a growth factor for certain tumors and contributes to…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE